Company intelligence / Profile preview
KSQ Therapeutics
Lexington, Massachusetts, United Statesksqtx.com ↗
- Ownership
- Private
- Employees
- ~92
- Development stage
- Phase 1
01
Overview
KSQ Therapeutics has advanced its lead program, KSQ‑004EX—a CRISPR/Cas9-edited TIL therapy targeting SOCS1 and Regnase‑1—into a Phase 1/2 clinical trial for solid tumors. Preclinical data showed that inactivation of these genes enhances anti-tumor activity of TILs. The company’s broader pipeline includes additional cancer immunotherapy programs at earlier stages.
- Therapeutic areas
- Oncology
- Modalities
- Adoptive cell therapies (CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes/eTIL)Targeted therapiesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Multiple pharma partnerships based on their target discovery platform; specific partners not named in provided results but referenced as “large pharma” collaborations.
Beyond the preview
Go deeper on KSQ Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KSQ Therapeutics.